Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Current Assets (2020 - 2025)

Historic Current Assets for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to $2.9 million.

  • Ensysce Biosciences' Current Assets fell 6778.76% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 6778.76%. This contributed to the annual value of $5.3 million for FY2024, which is 13350.77% up from last year.
  • Per Ensysce Biosciences' latest filing, its Current Assets stood at $2.9 million for Q3 2025, which was down 6778.76% from $5.3 million recorded in Q2 2025.
  • Ensysce Biosciences' Current Assets' 5-year high stood at $15.7 million during Q4 2021, with a 5-year trough of $2.3 million in Q4 2023.
  • Its 5-year average for Current Assets is $6.4 million, with a median of $5.3 million in 2022.
  • Per our database at Business Quant, Ensysce Biosciences' Current Assets surged by 866210.06% in 2021 and then tumbled by 7108.83% in 2023.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Current Assets stood at $15.7 million in 2021, then tumbled by 66.17% to $5.3 million in 2022, then plummeted by 56.81% to $2.3 million in 2023, then skyrocketed by 133.51% to $5.3 million in 2024, then plummeted by 45.21% to $2.9 million in 2025.
  • Its Current Assets was $2.9 million in Q3 2025, compared to $5.3 million in Q2 2025 and $4.4 million in Q1 2025.